Your browser is no longer supported. Please, upgrade your browser.
Chimerix, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own4.40% Shs Outstand86.33M Perf Week-7.09%
Market Cap544.22M Forward P/E- EPS next Y-0.28 Insider Trans-61.54% Shs Float82.78M Perf Month12.81%
Income-145.40M PEG- EPS next Q-0.34 Inst Own62.60% Short Float3.32% Perf Quarter-17.48%
Sales3.10M P/S175.55 EPS this Y65.50% Inst Trans9.11% Short Ratio3.18 Perf Half Y-24.55%
Book/sh1.21 P/B4.88 EPS next Y81.10% ROA-111.10% Target Price18.00 Perf Year59.89%
Cash/sh1.33 P/C4.44 EPS next 5Y- ROE-135.00% 52W Range3.38 - 11.57 Perf YTD22.15%
Dividend- P/FCF- EPS past 5Y23.50% ROI-60.60% 52W High-49.00% Beta1.42
Dividend %- Quick Ratio4.80 Sales past 5Y-13.00% Gross Margin- 52W Low74.56% ATR0.41
Employees54 Current Ratio4.90 Sales Q/Q-93.80% Oper. Margin- RSI (14)48.21 Volatility7.82% 7.98%
OptionableYes Debt/Eq0.13 EPS Q/Q-17.30% Profit Margin- Rel Volume0.68 Prev Close6.23
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume864.23K Price5.90
Recom1.70 SMA20-0.35% SMA50-1.55% SMA200-22.62% Volume583,490 Change-5.30%
Apr-29-21Initiated Maxim Group Buy $20
Apr-23-21Resumed Cowen Outperform $10 → $18
Mar-31-21Initiated Wedbush Outperform $21
Mar-31-21Initiated Jefferies Buy $21
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Nov-22-21 04:21AM  
Nov-19-21 07:00AM  
Nov-12-21 08:00AM  
Nov-11-21 07:00AM  
Nov-04-21 08:03PM  
Nov-01-21 08:00AM  
Oct-29-21 10:36AM  
Oct-28-21 03:05PM  
Sep-07-21 07:00AM  
Aug-07-21 06:01AM  
Aug-06-21 02:18AM  
Aug-05-21 07:00AM  
Aug-03-21 07:00AM  
Jul-29-21 07:00AM  
Jul-27-21 06:48PM  
Jul-01-21 06:58AM  
Jun-04-21 02:10PM  
May-25-21 08:00AM  
May-24-21 02:04AM  
May-19-21 05:01PM  
May-13-21 07:00AM  
May-07-21 09:01AM  
May-06-21 07:00AM  
May-05-21 06:40AM  
Apr-29-21 07:00AM  
Apr-28-21 11:43AM  
Apr-26-21 07:00AM  
Apr-08-21 04:01PM  
Mar-02-21 07:00AM  
Feb-26-21 01:44PM  
Feb-25-21 11:31PM  
Feb-18-21 07:00AM  
Jan-25-21 05:44PM  
Jan-20-21 08:03PM  
Jan-19-21 04:19PM  
Jan-11-21 10:29AM  
Jan-08-21 07:48PM  
Jan-06-21 08:00AM  
Dec-22-20 12:41AM  
Dec-12-20 10:30PM  
Dec-08-20 08:56AM  
Dec-07-20 07:00AM  
Nov-07-20 08:33AM  
Nov-06-20 05:50AM  
Nov-05-20 04:01PM  
Oct-29-20 07:00AM  
Oct-28-20 08:12AM  
Sep-13-20 10:21AM  
Sep-10-20 08:00AM  
Aug-10-20 08:25AM  
Aug-03-20 08:00AM  
Jul-15-20 12:22PM  
Jul-05-20 02:43PM  
Jun-22-20 07:00AM  
Jun-18-20 08:00AM  
May-28-20 08:00AM  
May-12-20 06:47AM  
May-07-20 10:25AM  
May-02-20 08:40AM  
Apr-29-20 07:00AM  
Apr-28-20 04:30PM  
Mar-26-20 08:18AM  
Mar-18-20 06:26AM  
Feb-28-20 12:00PM  
Feb-26-20 08:00AM  
Feb-25-20 07:00AM  
Feb-24-20 08:00AM  
Feb-18-20 08:00AM  
Feb-06-20 07:04AM  
Feb-05-20 11:52AM  
Jan-29-20 08:00AM  
Jan-03-20 11:30AM  
Dec-23-19 06:12AM  
Dec-16-19 01:04AM  
Dec-14-19 08:59PM  
Dec-10-19 07:30AM  
Dec-04-19 01:01AM  
Nov-22-19 12:02AM  
Nov-07-19 06:19AM  
Nov-05-19 07:00AM  
Nov-04-19 04:01PM  
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jakeman DavidPrincipal Accounting OfficerSep 30Sale6.194,59028,412106,066Sep 30 06:02 PM
CANTEX PHARMACEUTICALS, INC.10% OwnerSep 14Sale5.756,500,00037,375,0003,500,000Sep 16 04:05 PM
MIDDLETON FRED ADirectorJun 28Buy7.836,95054,418207,523Jun 29 05:37 PM
MIDDLETON FRED ADirectorJun 25Buy7.783,05023,729200,573Jun 29 05:37 PM
Jakeman DavidPrincipal Accounting OfficerApr 05Option Exercise2.355,25012,338103,989Apr 07 01:37 PM
Jakeman DavidPrincipal Accounting OfficerApr 05Sale9.681,28412,427102,705Apr 07 01:37 PM
Meyer Robert J.DirectorMar 01Buy9.801,50014,70015,000Mar 01 02:10 PM
Jakeman DavidPrincipal Accounting OfficerJan 28Sale8.613,21127,65096,906Jan 29 08:13 PM